Global Retirement Partners LLC Takes Position in Becton, Dickinson and Company $BDX

Global Retirement Partners LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, Holdings Channel.com reports. The fund acquired 7,783 shares of the medical instruments supplier’s stock, valued at approximately $1,178,000.

Several other hedge funds also recently modified their holdings of BDX. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. SHP Wealth Management bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at $26,000. Meeder Asset Management Inc. boosted its position in shares of Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 102 shares during the last quarter. Main Street Group LTD bought a new stake in Becton, Dickinson and Company in the 1st quarter worth about $29,000. Finally, Prosperity Bancshares Inc purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.6%

Shares of Becton, Dickinson and Company stock opened at $182.39 on Tuesday. The company has a market capitalization of $50.26 billion, a P/E ratio of 54.94, a P/E/G ratio of 12.93 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a fifty day moving average of $158.48 and a 200 day moving average of $161.26.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BDX. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research note on Friday, August 7th. Piper Sandler lifted their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. TD Cowen upped their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. The Goldman Sachs Group reduced their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 27th. Finally, Jefferies Financial Group restated a “buy” rating and set a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $185.67.

Insider Buying and Selling

In related news, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 11,779 shares of company stock valued at $1,974,669 in the last ninety days. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.